Zou Jun-Ju, Li Hong, Zhou Min, Huang Qiu-Qing, Wu Yong-Jun, Yu Rong
School of Traditional Chinese Medicine, Hunan University of Chinese Medicine Changsha 410208, China National Key Laboratory Cultivation Base of Chinese Medicinal Powder & Innovative Medicinal Jointly Established by Province and Ministry Changsha 410208, China.
School of Traditional Chinese Medicine, Hunan University of Chinese Medicine Changsha 410208, China.
Zhongguo Zhong Yao Za Zhi. 2023 Jan;48(2):525-533. doi: 10.19540/j.cnki.cjcmm.20220913.703.
This study aimed to investigate the recovery effect of Zuogui Jiangtang Qinggan Prescription on intestinal flora homeostasis control and intestinal mucosal barrier in type 2 diabetes mellitus(T2DM) with nonalcoholic fatty liver disease(NAFLD) induced by a high-fat diet. NAFLD was established in MKR transgenic mice(T2DM mice) by a high-fat diet(HFD), and subsequently treated for 8 weeks with Zuogui Jiangtang Qinggan Prescription(7.5, 15 g·kg(-1)) and metformin(0.067 g·kg(-1)). Triglyceride and liver function were assessed using serum. The hematoxylin-eosin(HE) staining and Masson staining were used to stain the liver tissue, while HE staining and AB-PAS staining were used to stain the intestine tissue. 16S rRNA sequencing was utilized to track the changes in the intestinal flora of the mice in each group. Polymerase chain reaction(PCR) and immunofluorescence were used to determine the protein and mRNA expression levels of ZO-1, Occludin, and Claudin-1. The results demonstrated that Zuogui Jiangtang Qinggan Prescription increased the body mass of T2DM mice with NAFLD and decreased the hepatic index. It down-regulated the serum biomarkers of liver function and dyslipidemia such as alanine aminotransferase(ALT), aspartate transaminase(AST), and triglycerides(TG), increased insulin sensitivity, and improved glucose tolerance. According to the results of 16S rRNA sequencing, the Zuogui Jiangtang Qinggan Prescription altered the composition and abundance of the intestinal flora, increasing the relative abundances of Muribaculaceae, Lactobacillaceae, Lactobacillus, Akkermansia, and Bacteroidota and decreasing the relative abundances of Lachnospiraceae, Firmicutes, Deslfobacteria, Proteobacteria, and Desulfovibrionaceae. According to the pathological examination of the intestinal mucosa, Zuogui Jiangtang Qinggan Prescritpion increased the expression levels of the tight junction proteins ZO-1, Occludin, and Claudin-1, promoted intestinal mucosa repair, protected intestinal villi, and increased the height of intestinal mucosa villi and the number of goblet cells. By enhancing intestinal mucosal barrier repair and controlling intestinal microbiota homeostasis, Zuogui Jiangtang Qinggan Prescription reduces intestinal mucosal damage induced by T2DM and NAFLD.
本研究旨在探讨左归降糖清肝方对高脂饮食诱导的2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)小鼠肠道菌群稳态调控及肠黏膜屏障的恢复作用。通过高脂饮食(HFD)在MKR转基因小鼠(T2DM小鼠)中建立NAFLD模型,随后分别用左归降糖清肝方(7.5、15 g·kg⁻¹)和二甲双胍(0.067 g·kg⁻¹)治疗8周。采用血清检测甘油三酯和肝功能。肝组织采用苏木精-伊红(HE)染色和Masson染色,肠组织采用HE染色和AB-PAS染色。利用16S rRNA测序追踪各组小鼠肠道菌群的变化。采用聚合酶链反应(PCR)和免疫荧光法检测紧密连接蛋白ZO-1、闭合蛋白和Claudin-1的蛋白及mRNA表达水平。结果表明,左归降糖清肝方增加了T2DM合并NAFLD小鼠的体重,降低了肝脏指数。下调了肝功能和血脂异常的血清生物标志物,如丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)和甘油三酯(TG),提高了胰岛素敏感性,改善了糖耐量。根据16S rRNA测序结果,左归降糖清肝方改变了肠道菌群的组成和丰度,增加了毛螺菌科、乳杆菌科、乳杆菌属、阿克曼菌属和拟杆菌门的相对丰度,降低了瘤胃菌科、厚壁菌门、脱硫杆菌属、变形菌门和脱硫弧菌科的相对丰度。根据肠黏膜病理检查,左归降糖清肝方提高了紧密连接蛋白ZO-1、闭合蛋白和Claudin-1的表达水平,促进了肠黏膜修复,保护了肠绒毛,增加了肠黏膜绒毛高度和杯状细胞数量。左归降糖清肝方通过增强肠黏膜屏障修复和调控肠道微生物群稳态,减轻了T2DM和NAFLD诱导的肠黏膜损伤。